Abstract
Introduction
Hip and knee device sales representatives (reps) can provide intra-operative guidance through their knowledge of the products, especially in complicated cases such as revision hip and knee arthroplasty. However, for an experienced arthroplasty surgeon in the majority of straightforward primary cases, the rep's presence may not be required for clinical decision-makings. With recent challenges in cost savings and bundle payments, hospitals and surgeons have focused on reducing the implant costs, among others, with a “repless” model. The aim of this study was to describe the process of utilizing this model, assess its efficacy, and analyze the cost savings in primary hip arthroplasty.
Methods
During the month of January 2016, 20 cases of primary, straightforward total hip arthroplasties were performed with the repless model by 2 experienced arthroplasty trained surgeons. All patients were followed prospectively for minimum 3 months. Prior to initiating the repless model, we focused on process management of the operating room with staff training and re-engineering of the trays to obtain a setup that included one hospital tray and one device company tray for each operation.
The responsibilities of the rep were divided into 2 categories for better management:
-
Familiarity of the instruments, implant, and techniques; trays set up and assurance of availability of the implants. These responsibilities were covered by a trained OR technician and the surgeon
-
Final verification of the accurate implants prior to opening the packaging. This was done by a trained OR nurse and the surgeon
Results
We did not have any intra-operative complications. We also did not encounted any issued with the trays or errors in opening of the implants. There were no re-admissions, fracture, dislocation, or infection. The mean length of stay was 2.2 ± 0.5 days (range 1–3 days) with 68% home discharges.
The cost of the implant was reduced from $4,800 to $1,895 with $2,905 cost saving per case and total savings of $58,100. The projected savings only for uncomplicated primary total hip arthroplasty (minimum 120 cases/year between 2 surgeons) is $384,600.
Further cost saving from the process management changes were seen in central sterile processing time. Prior to the one tray system, the hospital had 3 in-house trays and there were 4 device company trays. We also noticed an approximate 27% improvement in turnover time.
Conclusion
Repless model has significant cost saving potential. Preparation for the transition, proper patient selection, standardization of the trays and implants, and distribution of the responsibilities between OR nurses, technicians and the surgeon are essential.
